Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy

Jeremy G Baldwin,Christoph Heuser-Loy,Tanmoy Saha,Roland C Schelker,Dragana Slavkovic-Lukic,Nicholas Strieder,Inmaculada Hernandez-Lopez,Nisha Rana,Markus Barden,Fabio Mastrogiovanni,Azucena Martín-Santos,Andrea Raimondi,Philip Brohawn,Brandon W Higgs,Claudia Gebhard,Veena Kapoor,William G Telford,Sanjivan Gautam,Maria Xydia,Philipp Beckhove,Sina Frischholz,Kilian Schober,Zacharias Kontarakis,Jacob E Corn,Matteo Iannacone,Donato Inverso,Michael Rehli,Jessica Fioravanti,Shiladitya Sengupta,Luca Gattinoni

DOI: https://doi.org/10.1016/j.cell.2024.08.029

IF: 64.5

2024-09-12

Cell

Abstract:Mitochondrial loss and dysfunction drive T cell exhaustion, representing major barriers to successful T cell-based immunotherapies. Here, we describe an innovative platform to supply exogenous mitochondria to T cells, overcoming these limitations. We found that bone marrow stromal cells establish nanotubular connections with T cells and leverage these intercellular highways to transplant stromal cell mitochondria into CD8+ T cells. Optimal mitochondrial transfer required Talin 2 on both donor and recipient cells. CD8+ T cells with donated mitochondria displayed enhanced mitochondrial respiration and spare respiratory capacity. When transferred into tumor-bearing hosts, these supercharged T cells expanded more robustly, infiltrated the tumor more efficiently, and exhibited fewer signs of exhaustion compared with T cells that did not take up mitochondria. As a result, mitochondria-boosted CD8+ T cells mediated superior antitumor responses, prolonging animal survival. These findings establish intercellular mitochondrial transfer as a prototype of organelle medicine, opening avenues to next-generation cell therapies.